Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.42M 2.24M 2.09M 3.93M 262M 3.96M 26.64M 10.36M 129M 10.41M 10.19M 448M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.67M 8.02M 7.49M 14.06M 938M 14.16M 95.34M 37.1M 461M 37.27M 36.46M 1.6B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 70 01/03/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%+6.69%+73.05%+122.03% 56.65B
+4.00%+7.51%+63.67%+68.77% 47.49B
+1.34%-0.67%-15.34%-15.95% 22.81B
+1.46%+1.17%-3.97%+384.78% 21.37B
+1.30%+3.73%+27.10%-17.51% 16.12B
+2.87%+8.77%+25.09%-35.35% 15.56B
+0.25%-3.11%+27.20%+158.30% 12.91B
+3.30%+15.02%+133.24%+273.89% 12.86B
+1.43%-6.44%+21.49% - 11.67B
Average +1.99%+2.16%+39.06%+117.37% 24.16B
Weighted average by Cap. +2.15%+3.27%+45.39%+110.67%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.91 0.1 0.7 0.27 3.4 0.27 0.27 11.8 0.14 0.12 0.11 0.1 0.19 12.79 0.19 1.3 0.51 6.29 0.51 0.5 21.85
Net income -3.1M -2.71M -2.51M -2.34M -4.4M -293M -4.43M -29.82M -11.6M -144M -11.66M -11.4M -501M -18.47M -16.14M -14.93M -13.94M -26.16M -1.75B -26.36M -177M -69.04M -858M -69.36M -67.86M -2.98B
Net Debt 7.1M 6.2M 5.73M 5.35M 10.05M 671M 10.12M 68.15M 26.52M 330M 26.64M 26.06M 1.15B 7.15M 6.25M 5.78M 5.4M 10.13M 676M 10.2M 68.7M 26.73M 332M 26.86M 26.27M 1.15B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!